Patent: 9,133,518
✉ Email this page to a colleague
Summary for Patent: 9,133,518
| Title: | Method for determining predisposition to pulmonary infection |
| Abstract: | Provided herein are methods and materials for diagnosing a subject\'s predisposition for pulmonary infection in a CF subject by detecting a pulmonary infection genetic marker. Pulmonary infection markers have been identified in the IL-1 gene cluster and may be useful in predicting CF disease progression and assessing a CF subject\'s response to therapy. |
| Inventor(s): | Levy; Hara (Bayside, WI), Gerard; Craig (Chestnut Hill, MA), Pier; Gerald (Brookline, MA), Weiss; Scott (Chestnut Hill, MA), Lange; Christoph (Cambridge, MA) |
| Assignee: | Presidental and Fellows of Harvard College (Cambridge, MA) |
| Application Number: | 13/296,557 |
| Patent Claims: | see list of patent claims |
Details for Patent 9,133,518
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Swedish Orphan Biovitrum Ab (publ) | KINERET | anakinra | Injection | 103950 | 11/14/2001 | ⤷ Try a Trial | 2027-04-27 |
| Kiniksa Pharmaceuticals (uk), Ltd. | ARCALYST | rilonacept | For Injection | 125249 | 02/27/2008 | ⤷ Try a Trial | 2027-04-27 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
